All In Biotech

Drug Trial Radar · NCT03976063

Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation

Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation: a Double-blinded Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 857 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

857

Actual

Start

Oct 7, 2019

Primary completion

Nov 2026

Study completion Nov 2031

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France; Ministry of Health, France; Groupe de Recherche en Obstétrique et Gynécologie; URC-CIC Paris Descartes Necker Cochin
First posted
Jun 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess whether short-term (48 hr) tocolysis reduces perinatal morti-morbidity in cases of PPROM at 22 to 33 completed weeks' gestation.

Conditions

  • Preterm Premature Rupture of Membrane

Interventions

  • NifedipineDrug

    Loading dose: Oral Nifedipine 20 mg prolonged-release at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg prolonged-release at T3, then 1 pill every 8 hr for 48 hr (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)

  • Placebo of NifedipineDrug

    Oral Placebo of Nifedipine 20 mg, at T0, T0.5, T3, T11, T19, T27, T35 and T43

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Perinatal morti-morbidityTime frame: Up to discharge from hospital, with a maximum of 24 weeks after birth.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Trousseau University Hospital

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.